Clinical Trial Update: Intralymphatic Immunotherapy in Increasing Doses, After Subcutaneous Immunotherapy [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 clinical trial of intralymphatic immunotherapy with increasing doses following subcutaneous immunotherapy for allergic rhinitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Snippet

Sponsor: Karolinska Institutet | Conditions: Rhinitis, Allergic | Phase 2, Phase 3 | Status: COMPLETED